KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of SPH3127 Tablet, a Novel Direct Renin Inhibitor, in Patients with Mild-to-Moderate Essential Hypertension: A Phase III Randomised Trial.

Qiang Lv, Changsheng Ma, Fang Wang, Lipeng Li, Gang Xiong, Zhanquan Li, Yanling Qu, Wenyue Pang, Wenliang Xiao, Hongyun Ruan, Liping Wei, Gang Liu, Jun Zhang, Qiong Liu, Ling Lin, Mingzhi Long, Huanming Li, Hong Yuan, Ling Liu, Yue Gao, Peijing Liu, Cuntai Zhang, Zhirong Wang, Jianhong Xie, Jiguang Wang, Xin Zhang, Yongyi Lu, Kai Huang, Min Liu, Jiyan Chen, Xiaohong Gao, Dongfang Wang, Xueping Ma, Xiaoping Chen, Yuhui Li, Yue Zhang, Xiangqing Kong, Fang Chen, Xiaowei Zhang, Jie Qi, Yuanyuan Cao, Yaohua Huang, Yue Zhang, Weiwei Cui

Drugs 86(7) 1121-1132

PMID42165988
PMCIDPMC13290787
DOI10.1007/s40265-026-02315-z
发表日期2026-05-21
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:AI 判定为 flow diagram;Fig. 3:非 KM 图;Fig. 4:森林图/亚组分析图。
摘要

摘要

OBJECTIVE: To evaluate the efficacy and safety of sitokiren (SPH3127) tablet in patients with mild-to-moderate essential hypertension in comparison to valsartan capsule. METHODS: This multicentre, randomised, double-blind, parallel Phase III trial was designed in 2 stages. In the 1st stage, eligible patients were randomised to receive 50 mg, 100 mg or 200 mg of SPH3127 tablet or 80 mg of valsartan capsule once daily (QD) for 12 consecutive weeks. In the 2nd stage, eligible patients were randomised to receive assigned dose of SPH3127 tablet based on the results from the 1st stage or valsartan 80 mg QD for 12 consecutive weeks. Primary outcome was the change from baseline in mean sitting diastolic blood pressure (msDBP) at Week 12. Safety outcome measures included any adverse events. Exploratory outcomes included plasma concentration of SPH3127, as well as the assessment of the correlation between SPH3127 exposure with the level of renin inhibition, clinical efficacy and occurrence of adverse events. RESULTS: The 1st stage enrolled 189 patients, of which 129 eligible patients were randomised. High plasma renin activity (PRA) inhibitory effect (83%) and the biggest reduction of msDBP at Week 12 from baseline (- 8.17 ± 5.90 mmHg) was detected in SPH3127 group at the dosage of 100 mg, which was determined for the subsequent stage 2 of this trial. The 2nd stage screened 1260 patients, of which 828 eligible patients were randomised to receive SPH3127 tablet 100 mg (N = 413) and valsartan capsule 80 mg (N = 415), QD. Main analysis based on the treatment policy strategy indicated 5.97 (0.41) mmHg [least-square mean (LSM) and standard error (SE)] of the msDBP changes at Week 12 from baseline in the SPH3127 and 6.32 (0.41) in valsartan groups, with inter-group difference of - 0.35 mmHg (95% CI: - 1.48, 0.78, p = 0.005). Main analysis based on hypothetical strategy showed 5.95 (0.41) mmHg of the msDBP changes at Week 12 from baseline in the SPH3127 and 6.31 (0.42) mmHg in valsartan groups, with inter-group difference of - 0.36 mmHg (95% CI: - 1.51, 0.78, p = 0.006). During the 12-week treatment period, 250 (61.1%) patients in SPH3127 group and 231 (56.2%) patients in valsartan group reported treatment emergent adverse events (TEAEs). Adverse drug reaction (ADR) was reported by 34 (8.3%) and 41 (10.0%) patients in SPH3127 and valsartan group, respectively. The serious adverse events (SAEs) reported by 10 patients were considered not related to the investigational drugs. Death was reported in 1 patient in the valsartan group due to myocardial infarction, which was considered not related to the study drug. CONCLUSIONS: Oral SPH3127 tablet 100 mg QD is effective and safe for adult patients with mild-to-moderate essential hypertension. TRIAL REGISTRATION: Clinicaltrials.gov Identifier number NCT05359068.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Study design of stage 2. QD once daily, V Visit, W Week
非 KM Figure
Fig. 2Trial flowchart of the stage 2. ITT intention-to-treat, n number of patients, QD once daily, SS safety set
非 KM Figure
Fig. 3Main analyses of LSM changes of msDBP at Week 12 from baseline. Error bars represent SD. LSM least square means, msDBP mean sitting diastolic blood pressure, SD standard deviation
非 KM Figure
Fig. 4Subgroup analyses of mean sitting diastolic blood pressure (msDBP) reduction at Week 12 from baseline based on age, sex and baseline msDBP with A) treatment policy strategy and B) hypothetical strategy. Error bars represent standard deviation
非 KM Figure